P.4.a.016 Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study

Stein, Daniel J.; Ahokas, Antti; Fabiano, Antonella

doi:10.1016/s0924-977x(07)70784-8

Cited by 33 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The drug has shown efficacy in major depression. In one study in GAD, agomelatine was superior to placebo (Stein et al 2007a). The most commonly reported side effects are headache, nausea, and diarrhoea, but these adverse events at the same frequency as with placebo.…”

Section: )(D)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Section: )(D)mentioning

confidence: 99%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

show abstract

“…Two published randomized, placebo controlled trials (RCTs) evaluated agomelatine efficacy and tolerability in GAD. Stein et al (23) randomized 121 patients with GAD and no comorbid disorders to agomelatine (25-50 mg/day) or placebo for 12 weeks. Study results demonstrated significant superiority of agomelatine 25 to 50 mg as compared with placebo.…”

Section: Published Data On Agomelatine Treatment Ofadsmentioning

confidence: 99%

Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data

Berardis¹,

Conti

Marini³

et al. 2013

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Anxiety disorders (ADs) are the most common type of psychiatric disorders. Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic antidepressants (NaSSA) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Agomelatine, a new melatonergic antidepressant, has been shown effective in various types of mood disorders. Moreover, some evidence points towards a possible efficacy of such a drug in the treatment of ADs. Therefore, the aim of this review was to elucidate current (facts and views) data on the role of agomelatine in the treatment of ADs. The trials evaluating agomelatine in the treatment of generalized anxiety disorder are few but, overall, encouraging in regards to its efficacy. However, further randomized, placebo-controlled studies on larger samples use are needed. Apart from some interesting case reports, no large studies are, to date, present in literature regarding agomelatine in the treatment of other ADs, such as panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Therefore, the clinical efficacy and the relative good tolerability of agomelatine in generalized anxiety (GAD) warrants further investigation in ADs.

show abstract

“…33 Agomelatine's efficacy has also been explored in obsessive compulsive disorder in two recent studies. 34,35 Agomelatine has shown promise in seasonal affective disorder in a 14-week open-label study, where patients showed high response and remission rates.…”

Section: Other Disordersmentioning

confidence: 99%

Agomelatine: a review for general practitioners

Outhoff

2012

South African Family Practice

View full text Add to dashboard Cite

The 24-hour rhythms of life, including the timing of sleep induction, wakefulness, hormone secretion, thermoregulation, glucose homeostasis and fat metabolism, are governed by external environmental time signals AbstractAgomelatine is a novel melatonergic antidepressant that restores disrupted biological rhythms, essentially by resetting the circadian clock. Two different, non-monoaminergic, and possibly synergistic pathways, appear to be involved in its mechanism of action. Agomelatine is a melatonin 1 (MT 1 ) and melatonin 2 (MT 2 ) receptor agonist and serotonin (5-hydroxytryptamine) 2C (5-HT 2C ) receptor antagonist. It is effective in treating moderate-to-severe depression, alleviating the symptoms of anxiety, and restoring the disrupted sleep patterns that often result from this potentially devastating disease. Agomelatine is generally well tolerated with little, if any, propensity for antidepressant-induced sexual dysfunction, weight gain, or discontinuation reactions. However, it has the potential to cause temporary hepatotoxicity, and liver functions need to be monitored as a result. Clinically, meaningful drug interactions are unlikely, with the exception of co-administered potent cytochrome P 1A2 (CYP1A2) enzyme inhibitors, which may increase agomelatine's plasma levels significantly. Agomelatine represents an interesting addition to the antidepressant market.Peer reviewed.

show abstract

P.4.a.016 Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study

Cited by 33 publications

References 0 publications

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data

Agomelatine: a review for general practitioners

Contact Info

Product

Resources

About